Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies

Effective vaccines and monoclonal antibodies have been developed against coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). However, the appearance of virus variants with higher transmissibility and pathogenicity is a major concern because of...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulz, Sebastian R., Hoffmann, Markus, Roth, Edith, Pracht, Katharina, Burnett, Deborah L., Mazigi, Ohan, Schuh, Wolfgang, Manger, Bernhard, Mielenz, Dirk, Goodnow, Christopher C., Christ, Daniel, Pöhlmann, Stefan, Jäck, Hans‐Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Immunity to infection
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087419/
https://www.ncbi.nlm.nih.gov/pubmed/35253229
http://dx.doi.org/10.1002/eji.202249841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087419/
https://www.ncbi.nlm.nih.gov/pubmed/35253229
http://dx.doi.org/10.1002/eji.202249841

Ejemplares similares